Heparin-induced thrombocytopenia is a profoundly dangerous, potentially lethal, immunologically mediated adverse drug reaction to unfractionated heparin or, less commonly, to low-molecular weight heparin. In this comprehensive review, the authors highlight heparin-induced thrombocytopenia's risk factors, clinical presentation, pathophysiology, diagnostic principles, and treatment. The authors place special emphasis on the management of patients requiring procedures using cardiopulmonary bypass or interventions in the catheterization laboratory. Clinical vigilance of this disease process is important to ensure its recognition, diagnosis, and treatment. Misdiagnosis of the syndrome, as well as misunderstanding of the disease process, continues to contribute to its morbidity and mortality.
U nfractionated heparin (UFH) and other heparin derivatives, such as low-molecular weight heparin (LMWH), are among the most frequently prescribed medications worldwide (1) . They are routinely used for therapeutic and prophylactic anticoagulation in a multitude of medical and surgical conditions (2) . Although hemorrhagic events are the most common complication of heparin therapy, thrombotic complications are also possible in patients who develop heparininduced thrombocytopenia (HIT) (3) . Mortality associated with HIT is reported at between 20% and 30% (4, 5) .
HIT is a dangerous, potentially lethal, immunologically mediated adverse drug reaction to UFH or, less commonly, to LMWH (6, 7) . An older nomenclature defined 2 types of HIT: type I and type II (8) . Type I, seen in 10% to 30% of patients given heparin, was characterized by a benign, mild thrombocytopenia occurring in the first 2 days after heparin administration (9) . Platelet count spontaneously normalizes, even with continued heparin therapy, and is not associated with increased thrombotic risk (10) (11) (12) .
Type II refers to the antibody-mediated, potentially fatal disorder, now referred to as HIT, in which heparin therapy needs to be discontinued as soon as the diagnosis is suspected (10, 13, 14) . It also requires the implementation of an alternative anticoagulation strategy to prevent the development of HIT with thrombosis (HITT) (15) .
In this comprehensive review, we highlight HIT's risk factors, clinical presentation, pathophysiology, diagnostic principles, and treatment. We place special emphasis on the management of patients requiring procedures using cardiopulmonary bypass (CPB) or interventions in the catheterization laboratory.
Increased awareness of this condition among clinicians is important to ensure its early recognition and treatment, to avoid serious complications (1) . Misdiagnosis of the syndrome, as well as misunderstanding of the disease process, continues to contribute to its morbidity and mortality (11) .
INCIDENCE, EPIDEMIOLOGY, AND RISK FACTORS
Studies indicate that the prevalence of HIT ranges from 0.1% to 5.0% in patients receiving heparin (3, 8, 16, 17) , with about 25% to 50% of these patients developing HITT (9, 18) . The risk for developing HIT varies considerably according to several patientand drug-related factors (3, 8, 16) . The parameters most strongly associated with an increased risk for the development of HIT are: 1) the duration of heparin therapy;
2) the type and dose of heparin administered;
3) the indication for treatment; and 4) the patient's sex.
Prolonged exposure to heparin therapy (>5 days) has been shown to be a frequent risk factor for developing thrombocytopenia and the further development of HIT (19) (20) (21) .
UFH conveys a risk 10 times greater than that of LMWH (22-26), whereas the pentasaccharide fondaparinux is rarely associated with HIT, having been described in only a few case reports (27, 28) . Also, the origin of heparin affects the risk, with bovine UFH associated with a higher risk than porcine UFH (19, 29) . Therapeutic anticoagulation doses frequently result in greater platelet reductions; in HIT, however, even exposure to very small amounts of heparin (heparin flushes) can lead to the formation of HIT antibodies (21, 30) .
With regard to the indication for heparinization, surgical (particularly cardiac and orthopedic) or trauma patients (1% to 5%) have a far greater risk than medical or intensive care unit patients (<1%) for the development of HIT (31, 32) .
And finally, female patients have approximately twice the risk for developing HIT, often attributed to their increased immune responses (19, 20, 22, 23, 26, 33, 34) .
CLINICAL PRESENTATION
The main clinical presentation of HIT is thrombocytopenia. After heparin exposure, platelet numbers decline rapidly, sometimes by 50% or more from baseline. Platelet counts fall below 150 Â 10 9 /l in 90% of patients, with a median nadir of about 55 Â 10 9 /l (35) . There are 3 patterns of onset for HIT: rapid, typical, and delayed. Sixty percent of patients with HIT exhibit the typical pattern, resulting in a platelet decline 5 to 10 days after exposure. In 30% of cases, the onset pattern is rapid, where platelet numbers decline immediately post-exposure (4, 35) . Such a robust response can be the result of previous exposure to heparin in the past 100 days and residual antibody presence from heparin sensitization (35) .
Last, the remaining patients exhibit delayed-onset HIT, occurring an average of 9.2 days after initiating therapy; however, signs and symptoms can appear up to 3 weeks post-exposure (35) .
Frequently, post-surgical patients exhibit a unique bimodal pattern of platelet decline. Initially, they may develop thrombocytopenia on post-operative day 1, but this usually rebounds in 5 to 6 days (36-38).
A second decline in platelet count is more likely to be associated with HIT and should warrant further investigation (23, [37] [38] [39] [40] . Importantly, clinicians should use the new, post-operative platelet count as a baseline.
Although HIT is characterized by thrombocytopenia, the disease process results in a paradoxical, prothrombotic disorder, with an incidence of thrombosis ranging from 50% to 89% in untreated patients (1, 4, 6, 23, 41) . It can lead to devastating arterial and venous thromboembolic complications, including pulmonary embolism, mesenteric ischemia, ischemic limb necrosis, acute myocardial infarction, and stroke (5, 6, 8, 42) . Venous thromboses predominate over arterial thromboses in medical patients with HIT or following orthopedic surgery (40) , whereas arterial and venous thromboses occur with similar frequency following vascular and cardiac surgery in patients with HIT (7). Additionally, 10% to 20% of patients have localized skin necrosis at heparin injection sites (4, 5) , and up to 20% of patients can develop disseminated intravascular coagulation (43) .
However, when the clinical picture includes thrombocytopenia, it is important to review the multiple scenarios that should be included in the differential diagnosis. These disease processes include acute pulmonary embolism, end-stage renal disease, sepsis, and patients with recent CPB, indwelling arterial devices (e.g. intra-aortic balloon pump, ventricular assist device, extracorporeal membrane oxygenation), and medications (4, 44) .
CLINICAL SCORING SYSTEMS
The diagnosis of HIT involves both clinical and labo- Salter et al.
The first scoring system is the HIT Expert Proba- 
PATHOPHYSIOLOGY OF HIT
The Normally, plasma contains only trace levels of PF4, but the concentration can be increased 15-to 30-fold in the presence of a heparin infusion (40, 44) . In addition, elevated PF4 levels are seen in several different patient populations, including those with infection, diabetes, or renal disease, or in response to trauma or CPB (54) .
LABORATORY STUDIES
It is important to remember that laboratory studies Second, the degree of reactivity on immunoassay, designated by optical density, should guide diagnosis and treatment (62) (63) (64) . Studies have shown that higher overall optical density scores are more often associated with a positive serotonin release assay (63) and with higher risk for thrombosis (65) (66) (67) (68) .
Furthermore, repeating the ELISA using 2-point testing (discussed later) increases the specificity of HIT testing (69, 70) is diagnosed, reversal with vitamin K should occur because of its depletion of proteins C and S and the increased risk for venous limb gangrene (6, 77) .
Warfarin also increases the activated partial thromboplastin time (aPTT) and can lead to underdosing of the selected direct thrombin inhibitor (DTI) for treatment (78) .
Although rare and controversial, fondaparinux has also been reported to create a similar clinical condition to that of HIT; conversely, it has also been studied as a treatment alternative (79) (80) (81) (82) .
Cessation alone is not enough to prevent thrombotic events. The 30-day risk for subsequent thrombosis following the cessation of heparin therapy is estimated to be at least 19% and possibly as high as 52% (83) (84) (85) . This emphasizes the importance of beginning rapid-acting, alternate anticoagulation to reduce the heightened thrombin production and lessen the risk for thromboembolism. Table 3) .
BIVALIRUDIN. B a s i c c h a r a c t e r i s t i c s .
Bivalirudin is a DTI that is effective on both free and clot-bound In the most recent ACCP guidelines, HIT and HITT therapy with fondaparinux was not recommended, because of a lack of non-case-report-based evidence (6) . As previously mentioned, fondaparinux has been implicated as a causative agent of HIT.
However, additional studies have shown effective results and minimal cross-reactivity with HIT serum, making it an unlikely precipitating agent (27, (120) (121) (122) .
In a recent retrospective, propensity-matched study by Kang et al. (123) Further evidence suggests an association between warfarin therapy in patients with HIT and venous CrCl ¼ creatinine clearance; PCI ¼ percutaneous coronary intervention; other abbreviations as in Table 3 . 
HIT AND CPB
A patient with HIT who requires cardiac surgery is a particular challenge, requiring a team approach to provide optimal care (4, 143) . UFH is the gold standard anticoagulant for CPB, but patients with HIT may need to be administered alternative drugs (14) .
Patients requiring cardiac surgery with histories of HIT >100 days prior should have serologic testing, as HIT antibodies are transient and generally become nondetectable within 50 to 85 days (35) . If antibody is undetectable and platelet count has recovered, the ACCP recommendation is that patients can be safely re-exposed to heparin during cardiac surgery (4, 41, (144) (145) (146) . Although studies indicate that there is no amnestic immune response (35, 147) , these patients should be closely monitored for thrombocytopenia in the post-operative period, with a low threshold for prophylactic use of alternative anticoagulation (11) . Furthermore, heparin use should be limited to the procedure, with alternative anticoagulant agents used perioperatively (4,6,16).
However, in patients with subacute (detectable antibody and normal platelet counts) or acute HIT (antibody plus thrombocytopenia), re-exposure to heparin must be avoided, and an alternative strategy for anticoagulation is needed. The safety profiles of these alternatives are not well studied, and there are no known reversal agents (148) , so all attempts to delay the surgery should be made (4, 6, 41) . 
General Guidelines
Advance communication and planning with perfusion and surgery are critical.
Anesthesia staff should calculate in advance the likely amount of bivalirudin that will be required for the case and obtain it from the pharmacy.
All flush solutions, lines, and cell saver must be prepared with bivalirudin (0.1 mg/ml; 1 ml for every 5 ml cell saver processed) instead of heparin.
The bivalirudin is supplied as 250 mg/vial and is typically prepared as 250 mg in 50 ml (although 500 mg in 100 ml is probably more convenient).
Dosing
Initial bivalirudin load 
Monitoring
Keep kaolin ACT >500 s (or at least 2.5 times baseline).
• If <500 s, bolus 0.25 mg/kg and increase infusion by 0.25 mg/kg/h.
Avoid circulatory stasis. Use recirculation limbs and keep cardioplegia circulating if containing blood. Avoid hemofiltration during CPB to avoid removal of bivalirudin.
Management at the end of CPB Careful consideration of the likely success of separation from CPB is necessary, and the anesthesia, perfusion, and surgical teams should agree upon the strategy for termination of the bivalirudin infusion.
Stop infusion 10-15 min before weaning from CPB and then either:
• Empty pump into the cell saver system to remove bivalirudin and replace with crystalloid.
• Add 50 mg bivalirudin to the pump circuit, keep the blood recirculating (may require a cross limb bridge between the venous and arterial lines), and initiate 50 mg/h infusion into the bypass circuit, which should be continued until such time as it is clear that the patient will not require urgent return to CPB.
Ultrafiltration by the perfusionist can remove approximately 70% of the bivalirudin from the patient.
If separation from CPB does not occur within 20 min of stopping infusion, redose patient with 0.5 mg/kg and restart infusion at 2.5 mg/kg/h.
ACT ¼ activated clotting time; CPB ¼ cardiopulmonary bypass.
off-pump cardiac surgery to be a feasible alternative to heparin, without significantly increased mortality or morbidity, including bleeding ( should be achieved at the start of CPB, which corresponds to an ECT of 400 to 500 s or an ACT >500 s (14, 158) . Approximately 4 to 5 half-lives are needed for the effects of bivalirudin to be eliminated, unless their elimination is accelerated by hemodialysis or extracorporeal hemofiltration (148, 159, 160) . A treatment protocol for bivalirudin anticoagulation during CPB is in Table 6 .
Other areas of importance in regard to HIT and CPB include blood stasis and temperature management. It is critical to avoid blood stasis during CPB (4), because this allows bivalirudin metabolism to continue, increasing the risk for thrombus formation because of decreasing local bivalirudin levels, despite the presence of adequate systemic levels (148, 161) .
In addition, hypothermia reduces the proteolysis of bivalirudin; therefore, the patient's core temperature should be maintained close to 37 C following separation from CPB, and care should be taken to maintain body temperature during the early postoperative period (4).
HIT AND THE CATHETERIZATION LABORATORY
Argatroban, lepirudin, and bivalirudin have all been 
